Our Science – Tsang Website
Kwong Yok Tsang, Ph.D.
Selected Publications |
 |
| 1)
Schlom J, Hodge JW, Palena C, Greiner JW, Tsang KY, Farsaci B, Madan RA, Gulley JL. Prendergast G, Jaffee E, eds. Recombinant TRICOM-based therapeutic cancer vaccines: lessons learned. In: Cancer Immunotherapy. Elsevier; 2013. In Press. [Book Chapter] |
|
| 2)
Schlom J, Palena C, Gulley JL, Greiner JW, Tsang KY, Madan RA, Hodge JW. Lattime E, Gerson SL, eds. The use of T-cell costimulation to enhance the immunogenicity of tumors. In: Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation, Third Edition. Elsevier; 2013. In Press. [Book Chapter] |
|
| 3)
Huang J, Jochems C, Anderson AA, Talaie T, Jales A, Madan RA, Hodge JW, Tsang KY, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J. Soluble CD27-pool in humans may contribute to T-cell activation and tumor immunity. J Immunol. 2013. In Press. [Journal] |
|
| 4)
Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang K, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int. J. Cancer. [Epub ahead of print], 2013. [Journal] |
|
| 5)
Huen N, Pang AL, Tucker JA, Lee T, Vergati M, Jochems C, Intrivici C, Cereda V, Chan W, Rennert OM, Madan RA, Gulley JL, Schlom J, Tsang KY. Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. Int. J. Cancer. [Epub ahead of print], 2013. [Journal] |
|
| 6)
Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, Costarelli L, Litzinger M, Hamilton DH, Huang B, Tucker JA, Tsang KY, Schlom J, Palena C. Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res. 18: 3868-79, 2012. [Journal] |
|
| 7)
Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley JL, Schlom J. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood. 120: 3030-8, 2012. [Journal] |
|
| 8)
Mazor R, Vassall AN, Eberle JA, Beers R, Weldon JE, Venzon DJ, Tsang KY, Benhar I, Pastan I. Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc. Natl. Acad. Sci. U.S.A. 109: E3597-603, 2012. [Journal] |
|
| 9)
Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 13: 501-8, 2012. [Journal] |
|
| 10)
Kamrava M, Kesarwala AH, Madan RA, Lita E, Kaushal A, Tsang K, Poole DJ, Steinberg SM, Ferrara T, Dahut W, Schlom J, Gulley JL. Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy. Prostate Cancer Prostatic Dis. 15: 289-95, 2012. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 5/16/2013.
